NZ630721A - Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use - Google Patents

Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use

Info

Publication number
NZ630721A
NZ630721A NZ630721A NZ63072113A NZ630721A NZ 630721 A NZ630721 A NZ 630721A NZ 630721 A NZ630721 A NZ 630721A NZ 63072113 A NZ63072113 A NZ 63072113A NZ 630721 A NZ630721 A NZ 630721A
Authority
NZ
New Zealand
Prior art keywords
pyrazolo
pyrimidine
compositions
methods
based compounds
Prior art date
Application number
NZ630721A
Other languages
English (en)
Inventor
Kenneth Gordon Carson
Giovanni Cianchetta
Yingzhi Bi
Michael Alan Green
Godwin Kumi
Alan Main
Yulian Zhang
Glenn Gregory Zipp
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of NZ630721A publication Critical patent/NZ630721A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ630721A 2012-03-09 2013-03-05 Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use NZ630721A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608765P 2012-03-09 2012-03-09
PCT/US2013/029056 WO2013134228A1 (en) 2012-03-09 2013-03-05 PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

Publications (1)

Publication Number Publication Date
NZ630721A true NZ630721A (en) 2016-12-23

Family

ID=47892052

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630721A NZ630721A (en) 2012-03-09 2013-03-05 Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use

Country Status (25)

Country Link
US (3) US8946415B2 (https=)
EP (1) EP2834243B1 (https=)
JP (1) JP6418950B2 (https=)
KR (1) KR101965025B1 (https=)
CN (1) CN104302649B (https=)
AR (1) AR090292A1 (https=)
AU (1) AU2013230128B2 (https=)
BR (1) BR112014022000A8 (https=)
CA (1) CA2866143C (https=)
DK (1) DK2834243T3 (https=)
ES (1) ES2676224T3 (https=)
HU (1) HUE038786T2 (https=)
IL (1) IL234486A (https=)
IN (1) IN2014DN07384A (https=)
MX (2) MX381849B (https=)
NZ (1) NZ630721A (https=)
PL (1) PL2834243T3 (https=)
PT (1) PT2834243T (https=)
RU (1) RU2014140735A (https=)
SG (1) SG11201405561RA (https=)
TR (1) TR201808280T4 (https=)
TW (1) TW201341386A (https=)
UY (1) UY34668A (https=)
WO (1) WO2013134228A1 (https=)
ZA (1) ZA201406149B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302649B (zh) 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
WO2013134219A1 (en) 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
JP2016509066A (ja) 2013-02-22 2016-03-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アダプター関連キナーゼ１（ａａｋ１）の阻害剤としての５ｈ−クロメノ［３，４−ｃ］ピリジン
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
EP3054955B1 (en) 2013-10-11 2018-05-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2933350T3 (es) 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
MX2016009352A (es) * 2014-01-31 2016-10-13 Bristol Myers Squibb Co Inhibidores de quinasa a base de quinolina.
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法
WO2016053794A1 (en) * 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
CA2971024C (en) * 2014-12-15 2023-09-26 Handok Inc. Fused ring heteroaryl compounds and their use as trk inhibitors
ES2740224T3 (es) 2015-04-10 2020-02-05 Bristol Myers Squibb Co 6H-isocromeno[3,4-c]piridinas y benzo[c][1,7]naftiridin-6-(5H)-onas como inhibidores de la cinasa asociada a adaptador 1 (AAK1)
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RU2765181C2 (ru) 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
PT3733187T (pt) 2015-07-21 2024-11-08 Turning Point Therapeutics Inc Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro
ES2765738T3 (es) * 2015-11-02 2020-06-10 Janssen Pharmaceutica Nv Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
MX385576B (es) * 2016-11-02 2025-03-18 Janssen Pharmaceutica Nv Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2
CA3038916A1 (en) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
AU2017353313C1 (en) 2016-11-02 2022-06-09 Janssen Pharmaceutica Nv (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN111182903A (zh) 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途
SI3658557T1 (sl) 2017-07-28 2024-10-30 Takeda Pharmaceutical Company Limited Zaviralci TYK2 in njihova uporaba
SG11202005237SA (en) * 2017-12-15 2020-07-29 Pyramid Biosciences Inc 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
EP3730492A4 (en) * 2017-12-22 2021-08-11 Shenzhen TargetRx, Inc. SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US11345703B2 (en) 2018-01-23 2022-05-31 Shenzhen Targetrx, Inc. Substituted pyrazolo[1,5-a]pyrimidine macrocyclic compound
CN112771047A (zh) * 2018-09-27 2021-05-07 重庆复创医药研究有限公司 作为RET激酶抑制剂的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物
CN113271940A (zh) * 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
AU2021259419A1 (en) 2020-04-21 2022-11-10 Lexicon Pharmaceuticals, Inc. AAK1 inhibitors for use in treating viral infections
AU2021258128A1 (en) 2020-04-21 2022-11-03 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo(1,5-a)pyrimidin-5-yl)piperazine for use in the the treatment of COV-229E or COV-OC43 coronaviruses infections
US11478733B2 (en) 2020-11-24 2022-10-25 Caterpillar Inc. Filter interlock with tabs mating with a pedestal or a housing
AU2024338138A1 (en) * 2023-09-08 2026-03-19 Satellos Bioscience Inc. Ap2 associated kinase 1 inhibitors and uses thereof
WO2025230262A1 (ko) * 2024-04-29 2025-11-06 심플렉스 주식회사 신규한 헤테로아릴 유도체 및 이의 aak1 억제 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
KR101324804B1 (ko) * 2008-05-13 2013-11-01 아이알엠 엘엘씨 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
MY169791A (en) * 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8865726B2 (en) 2009-09-03 2014-10-21 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
WO2011087999A1 (en) * 2010-01-14 2011-07-21 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines as mark inhibitors
EP3812387A1 (en) * 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
WO2013134219A1 (en) 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
DK2822555T3 (en) * 2012-03-09 2018-02-05 Lexicon Pharmaceuticals Inc Inhibition of adapter-associated kinase 1 for the treatment of pain
CN104302649B (zh) 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法

Also Published As

Publication number Publication date
MX381849B (es) 2025-03-13
KR101965025B1 (ko) 2019-04-02
CA2866143A1 (en) 2013-09-12
EP2834243A1 (en) 2015-02-11
BR112014022000A2 (pt) 2017-06-20
DK2834243T3 (en) 2018-07-23
HK1201257A1 (en) 2015-08-28
AR090292A1 (es) 2014-11-05
US20170129896A1 (en) 2017-05-11
EP2834243B1 (en) 2018-04-25
UY34668A (es) 2013-10-31
CN104302649B (zh) 2017-06-23
PT2834243T (pt) 2018-08-01
TR201808280T4 (tr) 2018-07-23
US9403832B2 (en) 2016-08-02
ES2676224T3 (es) 2018-07-17
BR112014022000A8 (pt) 2021-06-15
IN2014DN07384A (https=) 2015-04-24
CN104302649A (zh) 2015-01-21
PL2834243T3 (pl) 2018-09-28
IL234486A (en) 2016-10-31
JP6418950B2 (ja) 2018-11-07
JP2015509535A (ja) 2015-03-30
KR20140138864A (ko) 2014-12-04
AU2013230128B2 (en) 2017-08-17
MX345830B (es) 2017-02-17
MX2014010589A (es) 2014-09-18
CA2866143C (en) 2020-08-04
US20150183792A1 (en) 2015-07-02
WO2013134228A1 (en) 2013-09-12
ZA201406149B (en) 2016-06-29
US8946415B2 (en) 2015-02-03
HUE038786T2 (hu) 2018-11-28
US20130253194A1 (en) 2013-09-26
SG11201405561RA (en) 2014-10-30
AU2013230128A1 (en) 2014-09-25
RU2014140735A (ru) 2016-04-27
TW201341386A (zh) 2013-10-16

Similar Documents

Publication Publication Date Title
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
NZ630719A (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
NZ702571A (en) 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
NZ600430A (en) Spiro-oxindole mdm2 antagonists
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
MX2010007714A (es) Piridinas fusionadas activas como inhibidores de c-met.
NZ629432A (en) Heterocyclyl compounds as mek inhibitors
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
NZ609957A (en) Heterocyclic compounds and uses thereof
PH12013501754A1 (en) Triazolopyridine compounds as pim kinase inhibitors
EA201290244A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
TN2009000142A1 (en) Bicyclic triazoles as protein kinase modulators
NZ703111A (en) Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
WO2011149950A3 (en) Bicyclic heteroaryl kinase inhibitors and methods of use
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
WO2012030944A3 (en) Quinoline and isoquinoline derivatives for use as jak modulators
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
NZ702513A (en) Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof
MX2014011326A (es) Derivados de 6-(4-(1-amino-3-hidroxiciclobutil) fenil)-5-fenil (furo, tieno o pirrolo) [2, 3-d] pirimidin 4-ona para el tratamiento de cancer.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 MAR 2020 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20170421

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2021 BY CPA GLOBAL

Effective date: 20200123

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2022 BY CPA GLOBAL

Effective date: 20210121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2023 BY CPA GLOBAL

Effective date: 20220121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2024 BY CPA GLOBAL

Effective date: 20230120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250116

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2027 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20260205